Uterine Carcinoma

Question 1

SYSTEMIC THERAPY FOR RECURRENT, METASTATIC, OR HIGH-RISK DISEASE
Endometrial carcinoma

Answer 1

Multi-agent chemotherapy regimens preferred, if tolerated
Carboplatin/paclitaxel
Cisplatin/doxorubicin
Cisplatin/doxorubicin/paclitaxel
Carboplatin/docetaxel
Ifosfamide/paclitaxel (category 1 for carcinosarcoma)
Cisplatin/ifosfamide (for carcinosarcoma)

Question 2

SYSTEMIC THERAPY FOR RECURRENT, METASTATIC, OR HIGH-RISK DISEASE
Single agents

Answer 2

Cisplatin 
Carboplatin 
Doxorubicin 
Liposomal doxorubicin 
Paclitaxel
Topotecan 
Bevacizumab
Temsirolimus
Docetaxel(category 2B) 
Ifosfamide (for carcinosarcoma)

Question 3

SYSTEMIC THERAPY FOR UTERINE SARCOMA

(Clinical trials strongly recommended) Combination regimens

Answer 3

• Docetaxel/gemcitabine (preferred for leiomyosarcoma)
• Doxorubicin/ifosfamide
• Doxorubicin/dacarbazine
• Gemcitabine/dacarbazine
• Gemcitabine/vinorelbine

Question 4

SYSTEMIC THERAPY FOR UTERINE SARCOMA

Single-agent options:

Answer 4

• Dacarbazine
• Doxorubicin
• Epirubicin
• Eribulin (category 2B)
• Gemcitabine
• Ifosfamide
• Liposomal doxorubicin
• Pazopanib
• Temozolomide
• Trabectedin
• Vinorelbine (category 2B)
• Docetaxel (category 3)